ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells.

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Etat: Public
Version: de l'auteur
Licence: CC BY 4.0
ID Serval
serval:BIB_321E5982053C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells.
Périodique
Frontiers in immunology
Auteur(s)
Lecciso M., Ocadlikova D., Sangaletti S., Trabanelli S., De Marchi E., Orioli E., Pegoraro A., Portararo P., Jandus C., Bontadini A., Redavid A., Salvestrini V., Romero P., Colombo M.P., Di Virgilio F., Cavo M., Adinolfi E., Curti A.
ISSN
1664-3224 (Print)
ISSN-L
1664-3224
Statut éditorial
Publié
Date de publication
2017
Peer-reviewed
Oui
Volume
8
Pages
1918
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Chemotherapy-induced immunogenic cell death can favor dendritic cell (DC) cross-priming of tumor-associated antigens for T cell activation thanks to the release of damage-associated molecular patterns, including ATP. Here, we tested the hypothesis that in acute myeloid leukemia (AML), ATP release, along with its well-known immune stimulatory effect, may also contribute to the generation of an immune suppressive microenvironment. In a cohort of AML patients, undergoing combined daunorubicin and cytarabine chemotherapy, a population of T regulatory cells (Tregs) with suppressive phenotype, expressing the immune checkpoint programmed cell death protein 1 (PD-1), was significantly increased. Moving from these results, initial in vitro data showed that daunorubicin was more effective than cytarabine in modulating DC function toward Tregs induction and such difference was correlated with the higher capacity of daunorubicin to induce ATP release from treated AML cells. DCs cultured with daunorubicin-treated AML cells upregulated indoleamine 2,3-dioxygenase 1 (IDO1), which induced anti-leukemia Tregs. These data were confirmed in vivo as daunorubicin-treated mice show an increase in extracellular ATP levels with increased number of Tregs, expressing PD-1 and IDO1+CD39+ DCs. Notably, daunorubicin failed to induce Tregs and tolerogenic DCs in mice lacking the ATP receptor P2X7. Our data indicate that ATP release from chemotherapy-treated dying cells contributes to create an immune suppressive microenvironment in AML.
Mots-clé
ATP, T regulatory cells, acute myeloid leukemia, chemotherapy, dendritic cell, immunosuppression
Pubmed
Web of science
Open Access
Oui
Création de la notice
22/01/2018 12:04
Dernière modification de la notice
30/04/2021 6:36
Données d'usage